Le Lézard
Classified in: Health
Subjects: PLW, MAT

GeneticsCubed Submits First Cannabichromene (CBC) Patent


HURRICANE, Utah, Nov. 17, 2020 /PRNewswire/ -- GeneticsCubed, a Green Rock Hemp Holdings company, has achieved a huge milestone in its mission to be a scientific innovator and produce the highest performance seeds and clones in the hemp industry. The company recently submitted the first patent for a unique Cannabichromene (CBC) hemp cultivar, C2B. "C2B is a high CBC hemp strain developed by selective breeding and high throughput screening of more than one million hemp plants," stated scientist Thomas Azwell, Ph.D.

Cannabichromene (CBC) is a rare, high-value cannabinoid, one of the most prominent in medical research. It is considered to have great potential for its antimicrobial, anti?inflammatory, and analgesic characteristics. "Although CBC has great therapeutic potential, it is a minor cannabinoid, meaning it occurs in very small amounts. This exceptional C2B cultivar tests as high as 4 percent CBC, which is 10 times the amount of commercially available 'high' CBC strains," Azwell stated. Early research indicates CBC's potential for treating acne, pain, and cancer by inhibiting inflammation. "The market value of CBC is significantly higher than CBD, and it currently sells for more than 20 times the price," commented Azwell.

"This was a huge accomplishment for our genetics team," stated Joseph Cachey, Chief Executive Officer, Green Rock Hemp Holdings. "The submission of this patent demonstrates our commitment to innovation and bringing scientific rigor to hemp cultivation. The Green Rock Hemp Holdings family of companies is dedicated to providing vertical solutions to the industrial hemp community."

In collaboration with the University of California-Berkeley, GeneticsCubed improves hemp with elevated levels of key cannabinoids. GeneticsCubed has also completed development of two other novel strains and will be submitting additional patent applications this year.

GeneticsCubed, LLC, part of the Green Rock Hemp Holdings family of companies, is a scientific innovator and leading supplier of premium hemp seeds and solutions for farmers and growers. Through scientific research, cutting-edge genetics, and multifaceted cannabis breeding expertise, our goal is to produce the highest performance seeds and clones in the market and enhance yields and profit margins for commercial farmers and growers.

For more information, please visit our website or contact Green Rock Hemp Holdings: 435-673-4125.

Related Images

geneticscubed-logo.jpg
GeneticsCubed logo

 

SOURCE GeneticsCubed, LLC


These press releases may also interest you

at 21:10
Aurora Spine Corporation ("Aurora Spine" or the "Company") , a leader in spine and interventional spine technology that improves spinal surgery outcomes, today announced its financial results for first quarter ended March 31, 2024. All figures...

at 20:43
PAVmed Inc.  ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business...

at 20:35
Cue Health Inc. , a healthcare technology company (the "Company"), has received a warning letter from the FDA about its Emergency Use Authorized (EUA) COVID-19 test. The Company is currently evaluating the letter and determining its response, with...

at 19:35
CV Sciences, Inc.  (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced that it has consummated...

at 19:32
Kodiak Sciences Inc. , a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that the first patients with diabetic retinopathy...

at 19:21
Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet need, today announced that the Center for Drug...



News published on and distributed by: